Lilian Bu

793 total citations
11 papers, 552 citations indexed

About

Lilian Bu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Lilian Bu has authored 11 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 2 papers in Surgery. Recurrent topics in Lilian Bu's work include Gastric Cancer Management and Outcomes (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Lilian Bu is often cited by papers focused on Gastric Cancer Management and Outcomes (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Lilian Bu collaborates with scholars based in China, United States and South Korea. Lilian Bu's co-authors include Manish A. Shah, Yoon‐Koo Kang, Niall C. Tebbutt, Alice Y. Kang, David S. Shames, Y. Choi, Yongzhe Piao, Shiying Yu, Hongming Pan and Lin Shen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Oncologist.

In The Last Decade

Lilian Bu

10 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lilian Bu China 7 450 356 117 111 94 11 552
Yoshinori Hirashima Japan 13 238 0.5× 335 0.9× 93 0.8× 155 1.4× 98 1.0× 29 572
Makio Gamoh Japan 11 248 0.6× 328 0.9× 109 0.9× 60 0.5× 95 1.0× 49 484
Anghel Adrian Udrea United States 8 227 0.5× 261 0.7× 96 0.8× 96 0.9× 58 0.6× 15 392
David E. Adelberg United States 13 305 0.7× 317 0.9× 170 1.5× 85 0.8× 106 1.1× 37 542
Jean‐Marie Tigaud France 13 387 0.9× 477 1.3× 191 1.6× 89 0.8× 100 1.1× 20 736
Fernando Rivera Spain 13 372 0.8× 331 0.9× 174 1.5× 157 1.4× 92 1.0× 27 612
Lawrence P. Leichman United States 11 239 0.5× 379 1.1× 217 1.9× 109 1.0× 34 0.4× 29 563
Marta Caporale Italy 11 150 0.3× 253 0.7× 119 1.0× 114 1.0× 33 0.4× 16 427
Rita P. Dalal United States 10 311 0.7× 415 1.2× 144 1.2× 92 0.8× 103 1.1× 21 622
M Starnawski Austria 3 660 1.5× 466 1.3× 271 2.3× 195 1.8× 268 2.9× 5 862

Countries citing papers authored by Lilian Bu

Since Specialization
Citations

This map shows the geographic impact of Lilian Bu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilian Bu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilian Bu more than expected).

Fields of papers citing papers by Lilian Bu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lilian Bu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilian Bu. The network helps show where Lilian Bu may publish in the future.

Co-authorship network of co-authors of Lilian Bu

This figure shows the co-authorship network connecting the top 25 collaborators of Lilian Bu. A scholar is included among the top collaborators of Lilian Bu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lilian Bu. Lilian Bu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Zhou, Caicun, You Lu, Sang‐We Kim, et al.. (2024). Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study. JTO Clinical and Research Reports. 5(9). 100700–100700. 2 indexed citations
3.
Wu, Yi‐Long, Shun Lü, Gongyan Chen, et al.. (2024). IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer. Chinese Journal of Cancer Research. 36(2). 103–113. 2 indexed citations
4.
Shi, Yuankai, Xin Zhang, Gang Wu, et al.. (2022). Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study. The Lancet Regional Health - Western Pacific. 23. 100452–100452. 10 indexed citations
5.
Zhou, Caicun, Sang-We Kim, Thanyanan Reungwetwattana, et al.. (2019). Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 7(5). 437–446. 186 indexed citations
6.
Si, Lu, Xiaoshi Zhang, Zhen Xu, et al.. (2018). Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. BMC Cancer. 18(1). 520–520. 9 indexed citations
7.
Shah, Manish A., Y. Choi, Iain Beehuat Tan, et al.. (2016). A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. The Oncologist. 21(9). 1085–1090. 91 indexed citations
8.
9.
Shah, Manish A., Y. Choi, Niall C. Tebbutt, et al.. (2015). Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).. Journal of Clinical Oncology. 33(3_suppl). 2–2. 38 indexed citations
10.
11.
Shah, Manish A., Eric Van Cutsem, Yoon‐Koo Kang, et al.. (2012). Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.. Journal of Clinical Oncology. 30(4_suppl). 5–5. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshinori Hirashima Breakdown of academic impact, for papers by Makio Gamoh Breakdown of academic impact, for papers by Anghel Adrian Udrea Breakdown of academic impact, for papers by David E. Adelberg Breakdown of academic impact, for papers by Jean‐Marie Tigaud Breakdown of academic impact, for papers by Fernando Rivera Breakdown of academic impact, for papers by Lawrence P. Leichman Breakdown of academic impact, for papers by Marta Caporale Breakdown of academic impact, for papers by Rita P. Dalal Breakdown of academic impact, for papers by M Starnawski
Rankless by CCL
2026